ChartMill · Sep 28, 2026
Monday's after hours session: top gainers and losers
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
GN
NASDAQ · GNPX
Genprex, Inc.
Healthcare · Biotechnology
$2.51
Down-$0.18 (-7.17%)
Updated Oct 14, 2026, 10:44 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 5.29M
- P/E ratio
- -0.15
- Dividend yield
- 0.00%
- 52-week range
- $0.42 – $12.61
- Volume
- 171K
- Avg. volume
- 716.01K
Price performance · GNPX
GNPX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
GNPX closed at $2.51 after 21 trading sessions, down 24.17% for the selected period.
- Last close
- $2.51
- Period change
- -24.17%
- Period low
- $2.51
- Period high
- $3.75
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $2.65 | $2.6916 | $2.51 | $2.51 | 171K |
| Oct 12, 2026 | $2.88 | $2.88 | $2.57 | $2.69 | 283.45K |
| Oct 9, 2026 | $2.81 | $2.93 | $2.64 | $2.72 | 202.27K |
| Oct 8, 2026 | $2.69 | $2.81 | $2.659 | $2.75 | 252.43K |
| Oct 7, 2026 | $2.62 | $2.78 | $2.58 | $2.62 | 227.57K |
| Oct 6, 2026 | $2.74 | $2.75 | $2.58 | $2.61 | 165.26K |
| Oct 5, 2026 | $2.67 | $2.81 | $2.61 | $2.72 | 151.73K |
| Oct 2, 2026 | $2.56 | $2.75 | $2.55 | $2.63 | 118.89K |
| Oct 1, 2026 | $2.98 | $2.98 | $2.5302 | $2.56 | 148.26K |
| Sep 30, 2026 | $2.82 | $3.06 | $2.76 | $2.92 | 181.44K |
| Sep 29, 2026 | $2.82 | $2.90 | $2.73 | $2.85 | 103.45K |
| Sep 28, 2026 | $3.41 | $3.41 | $2.70 | $2.81 | 568.37K |
| Sep 25, 2026 | $3.54 | $3.55 | $3.2601 | $3.29 | 119.92K |
| Sep 24, 2026 | $3.66 | $3.66 | $3.36 | $3.52 | 248.94K |
| Sep 23, 2026 | $3.76 | $4.20 | $3.42 | $3.75 | 2.5M |
| Sep 22, 2026 | $3.54 | $3.60 | $3.47 | $3.54 | 108.88K |
| Sep 21, 2026 | $3.48 | $3.65 | $3.46 | $3.48 | 116.91K |
| Sep 18, 2026 | $3.45 | $3.60 | $3.37 | $3.45 | 57.57K |
| Sep 17, 2026 | $3.50 | $3.58 | $3.34 | $3.46 | 74.37K |
| Sep 16, 2026 | $3.35 | $3.41 | $3.26 | $3.41 | 27.4K |
| Sep 15, 2026 | $3.45 | $3.475 | $3.30 | $3.31 | 25.78K |
Latest GNPX news
The latest Smart Investors Daily articles mentioning GNPX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GNPX research
Overview
Company profile and research snapshot.
Company profile
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $7.65
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 17, 2024 | HC Wainwright & Co. | Buy | — |
| May 15, 2024 | HC Wainwright & Co. | Buy | — |
| Apr 4, 2024 | HC Wainwright & Co. | Buy | — |
| Apr 3, 2024 | HC Wainwright & Co. | Buy | — |
| Mar 25, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 8, 2026
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), today announced that members of its executive leadership team will present at and participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16 in New York City. Genprex is a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function in cancer and insulin-producing function in diabetes. The Company's lead oncology program is in clinical developmen
Yahoo · Sep 1, 2026
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
Andelyn Biosciences, a leading contract development and manufacturing organization, announced today that Genprex, Inc. has selected Andelyn to support scale-up manufacturing for its diabetes gene therapy program.
Benzinga · Aug 17, 2026
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out today.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
